(CATX) Perspective Therapeutics - Ratings and Ratios
Alpha-Emitting Radiopharmaceuticals, Neuroendocrine Tumor Therapy, Melanoma Therapy, Prostate Cancer Therapy
CATX EPS (Earnings per Share)
CATX Revenue
Description: CATX Perspective Therapeutics October 27, 2025
Perspective Therapeutics Inc. (NYSE MKT: CATX) is a Seattle-based biotech that focuses on precision-targeted alpha-particle therapies (TAT) for oncology, leveraging the high linear energy transfer of alpha emitters to kill cancer cells while sparing surrounding tissue.
The company’s lead candidate, VMT-a-NET, is in a Phase 1/2a trial for unresectable or metastatic neuroendocrine tumors that express somatostatin receptor type 2 (SSTR2) and have not received prior peptide-targeted radiopharmaceuticals such as Lutathera. Parallel programs include VMT01 (Phase 1/2a for MC1R-positive metastatic melanoma), PSV359 (fibroblast activation protein-alpha targeted), and PSV4XX (PSMA-targeted for prostate cancer). All are designed to deliver ^212Pb-based alpha radiation.
Perspective has a clinical-trial collaboration with Bristol Myers Squibb to assess [^212Pb] VMT01 in combination with nivolumab, potentially expanding its immuno-oncology footprint. As of the latest filing, the company reported a cash runway of roughly $30 million, R&D spend of ~ $12 million in the last twelve months, and a market-cap of ≈ $70 million, indicating a need for additional financing to advance multiple INDs to pivotal stages.
Given the projected CAGR of 12-15 % for the U.S. radiopharmaceutical market and growing reimbursement support for targeted therapies, Perspective’s alpha-therapy platform aligns with a high-growth sector, but execution risk remains high due to early-stage clinical data and capital constraints.
For a deeper, data-driven look at CATX’s valuation dynamics and comparable peer metrics, you may find the analysis on ValueRay worth a quick review.
CATX Stock Overview
| Market Cap in USD | 193m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2005-11-10 |
CATX Stock Ratings
| Growth Rating | -27.3% |
| Fundamental | 26.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -83.7% |
| Analyst Rating | 4.64 of 5 |
CATX Dividends
Currently no dividends paidCATX Growth Ratios
| Growth Correlation 3m | -48.6% |
| Growth Correlation 12m | 0.4% |
| Growth Correlation 5y | -23% |
| CAGR 5y | -9.02% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.10 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.21 |
| Sharpe Ratio 12m | -2.35 |
| Alpha | -102.14 |
| Beta | 1.157 |
| Volatility | 101.75% |
| Current Volume | 1540.8k |
| Average Volume 20d | 1361.2k |
| Stop Loss | 2 (-8.7%) |
| Signal | -1.43 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-113.6m TTM) > 0 and > 6% of Revenue (6% = 34.6k TTM) |
| FCFTA -0.36 (>2.0%) and ΔFCFTA -29.82pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 31.8k% (prev 12.6k%; Δ 19.1kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -58.7m > Net Income -113.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 15.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (70.7m) change vs 12m ago 6.04% (target <= -2.0% for YES) |
| Gross Margin -150.2% (prev 35.57%; Δ -185.7pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.17% (prev 0.58%; Δ -0.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -493.8 (EBITDA TTM -117.2m / Interest Expense TTM 243.0k) >= 6 (WARN >= 3) |
Altman Z'' -7.63
| (A) 0.59 = (Total Current Assets 196.0m - Total Current Liabilities 13.0m) / Total Assets 310.7m |
| (B) -0.87 = Retained Earnings (Balance) -271.4m / Total Assets 310.7m |
| (C) -0.34 = EBIT TTM -120.0m / Avg Total Assets 348.3m |
| (D) -6.02 = Book Value of Equity -271.3m / Total Liabilities 45.0m |
| Total Rating: -7.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 26.16
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda 0.23 = 2.46 |
| 6. ROIC - WACC (= -49.02)% = -12.50 |
| 7. RoE -38.87% = -2.50 |
| 8. Rev. Trend -82.29% = -6.17 |
| 9. EPS Trend -52.45% = -2.62 |
What is the price of CATX shares?
Over the past week, the price has changed by -19.78%, over one month by -36.89%, over three months by -39.67% and over the past year by -81.41%.
Is Perspective Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CATX is around 1.90 USD . This means that CATX is currently overvalued and has a potential downside of -13.24%.
Is CATX a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CATX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.7 | 525.6% |
| Analysts Target Price | 13.7 | 525.6% |
| ValueRay Target Price | 2.2 | -1.8% |
CATX Fundamental Data Overview November 05, 2025
P/S = 156.3431
P/B = 0.9755
Beta = 1.157
Revenue TTM = 576.0k USD
EBIT TTM = -120.0m USD
EBITDA TTM = -117.2m USD
Long Term Debt = 1.60m USD (from longTermDebt, last quarter)
Short Term Debt = 901.0k USD (from shortTermDebt, last quarter)
Debt = 1.92m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -26.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.42m USD (193.1m + Debt 1.92m - CCE 191.6m)
Interest Coverage Ratio = -493.8 (Ebit TTM -120.0m / Interest Expense TTM 243.0k)
FCF Yield = -3284 % (FCF TTM -112.4m / Enterprise Value 3.42m)
FCF Margin = -19.5k% (FCF TTM -112.4m / Revenue TTM 576.0k)
Net Margin = -19.7k% (Net Income TTM -113.6m / Revenue TTM 576.0k)
Gross Margin = -150.2% ((Revenue TTM 576.0k - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = -203.0% (prev -114.0%)
Tobins Q-Ratio = 0.01 (Enterprise Value 3.42m / Total Assets 310.7m)
Interest Expense / Debt = 6.20% (Interest Expense 119.0k / Debt 1.92m)
Taxrate = 4.97% (-2.10m / -42.2m)
NOPAT = -114.0m (EBIT -120.0m * (1 - 4.97%)) [loss with tax shield]
Current Ratio = 15.09 (Total Current Assets 196.0m / Total Current Liabilities 13.0m)
Debt / Equity = 0.01 (Debt 1.92m / totalStockholderEquity, last quarter 265.7m)
Debt / EBITDA = 0.23 (negative EBITDA) (Net Debt -26.9m / EBITDA -117.2m)
Debt / FCF = 0.24 (negative FCF - burning cash) (Net Debt -26.9m / FCF TTM -112.4m)
Total Stockholder Equity = 292.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.57% (Net Income -113.6m / Total Assets 310.7m)
RoE = -38.87% (Net Income TTM -113.6m / Total Stockholder Equity 292.4m)
RoCE = -40.82% (EBIT -120.0m / Capital Employed (Equity 292.4m + L.T.Debt 1.60m))
RoIC = -38.78% (negative operating profit) (NOPAT -114.0m / Invested Capital 294.0m)
WACC = 10.24% (E(193.1m)/V(195.0m) * Re(10.28%) + D(1.92m)/V(195.0m) * Rd(6.20%) * (1-Tc(0.05)))
Discount Rate = 10.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.45%
Fair Price DCF = unknown (Cash Flow -112.4m)
EPS Correlation: -52.45 | EPS CAGR: 1.29% | SUE: 2.70 | # QB: 1
Revenue Correlation: -82.29 | Revenue CAGR: -51.55% | SUE: 0.07 | # QB: 0
Additional Sources for CATX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle